Skip to Main Content

Paper Details

Long COVID After Bamlanivimab Treatment.
J Infect Dis
0
2023
Bamlanivimab, COVID, COVID-19, acute respiratory syndrome, bamlanivimab, coronavirus 2 RNA, coronavirus disease 2019, participants
Author NameAffiliation
David A WohlUniversity of North Carolina at Chapel Hill.
Eric S DaarLundquist Institute, Harbor-university of california los angeles Medical Center
Joseph J EronUniversity of North Carolina at Chapel Hill.
Judith S CurrierDavid Geffen School of Medicine, University of California los angeles
Judith S CurrierDavid Geffen School of Medicine, University of California los angeles
  • 1 - 5

Datasets